MedTrace Logo

REVIVE Prospective Registry Cohort Study

NCT07429890 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2026-06-18

No results posted yet for this study

Summary

The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.

Conditions

  • Oropharyngeal Dysphagia

Interventions

OTHER

Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention.

Participants are followed observationally to collect long-term safety and effectiveness data after prior receipt of iltamiocel in the separate Revive clinical trial; no intervention is administered as part of this registry. Long-term safety outcomes and efficacy will be separated in analysis \& reporting

Sponsors & Collaborators

Principal Investigators

  • Peter Belafsky, MD · University of California, Davis

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-30
Primary Completion
2031-06-30
Completion
2032-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07429890 on ClinicalTrials.gov